辉瑞与特朗普的交易:药品定价新篇章,还是政治作秀?
此举或能博取头条,却可能无法解决美国药品定价的结构性问题。
DeeperDive is a beta AI feature. Refer to full articles for the facts.
本文由AI辅助翻译
辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)与美国总统唐纳德·特朗普(Donald Trump)于9月30日在白宫宣布的最新协议,究竟是药品定价领域的突破性转变,还是一场精心策划的政治表演——这取决于你的立场。
该协议包含大幅降价,辉瑞将对其多款最畅销的药物提供50%至85%的折扣。除了价格让步,辉瑞还承诺在美国国内的生产设施投资700亿美元,并获得为期三年的美国产药品关税豁免。
这些药品将通过一个新的政府网站TrumpRx提供,标志着一种绕开传统药店和保险渠道、直接面向消费者的非同寻常的模式。
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report